SOFINNOVA-PARTNERS
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Dr. Joe Anderson as Partner in the Sofinnova Crossover Fund, effective immediately.
Dr. Anderson has over 25 years’ experience in the healthcare and life sciences industries. Previously, he was a Partner at Abingworth LLP for over a decade, where he led venture-style investments in public companies and the formation of the firm’s public equities fund. Most recently, Dr. Anderson was Co-Founder and Chief Executive Officer at Arix Bioscience plc, a venture capital firm listed on the London Stock Exchange.
Dr. Anderson has substantial experience as an active Board Member developing innovative life sciences companies in the UK and the US and his investments have involved numerous private and public financing rounds, IPOs, M&As and exits.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, commented: “Joe’s arrival signals a decisive moment of growth for the Sofinnova Crossover Fund. It comes on the heels of a number of recent milestones, including two IPOs on the Nasdaq, new investments, positive clinical data and key appointments in our portfolio companies. His extensive experience leading venture capital investments in private and public companies will allow us to continue building on the great work of the Crossover team and positions Sofinnova Partners for further expansion.”
Joe Anderson commented: “I am delighted to join Sofinnova Partners at this exciting time for life sciences in Europe. The firm has been a pioneer in life sciences investing, most recently through the founding of the Sofinnova Crossover Fund -- one of the first of its kind in Europe. Record numbers of companies are being formed from a flourishing science base in Europe. Access to later-stage scale-up capital is crucial as they seek to build and retain value and the need for this kind of investment has never been greater. I look forward to working with my colleagues to further develop this leading European strategy.”
Jacques Theurillat, Partner in the Sofinnova Crossover Fund, commented: “We warmly welcome Joe to the Sofinnova Crossover team. Joe’s knowledge and expertise will further reinforce our experienced team of investment partners, Kinam Hong, Cédric Moreau, Tom Burt and myself, as we support ground-breaking innovations and enable later-stage life sciences companies to reach their full potential.”
Dr. Anderson began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became Head of the strategy group. He then moved to the City as a pharmaceuticals analyst at Dresdner Kleinwort Benson, before being appointed Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. He then joined Abingworth LLP as a Partner for 12 years before moving on to co-found Arix Biosciences in 2016 and lead its IPO on the London Stock Exchange the following year. He holds a Ph.D. in Biochemistry.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005998/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GeologicAI Announces Acquisition of Lumo Analytics to Complete Its Integrated Sensor Suite Across Critical Minerals and Rare Earth Elements17.12.2025 17:53:00 CET | Press release
GeologicAI, the global leader in High-Resolution Decision Engineering for the critical minerals sector, today announced its acquisition of Lumo Analytics, a provider of the most compact and efficient Laser-Induced Breakdown Spectroscopy (LIBS) scanner in the market. LIBS is a rapid, non-destructive technique that uses a high-energy laser pulse to vaporize a tiny spot on a rock, creating a short-lived plasma which emits light unique to the elements present when it cools. This spectral “fingerprint” provides immediate chemical information about the material. For the mining sector, this means faster geochemical insights directly at the source, enabling more efficient exploration and resource evaluation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217715846/en/ The transaction firmly cements GeologicAI’s position as the only truly comprehensive and integrated source of sensor data for the critical minerals industry. Buildi
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma17.12.2025 17:20:00 CET | Press release
Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible patients in Europe with relapsed or refractory FLPatients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide in the Phase 3 inMIND registration trialIn Western countries, including Europe, relapsed or refractory FL affects 2-4 out of every 100,000 people1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy. "The EC approval of Minjuvi addresses a critical need, bringing a new, first-of-its-kind, chemotherapy-free option to patients in Europe with relapsed or refractory FL,” said Bi
Rigaku Launches ONYX 3200, a Metrology Instrument for Semiconductor Manufacturing17.12.2025 16:00:00 CET | Press release
Enables complete metal inspection for all processes from chip wiring to advanced packaging on a single platform Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) announced the launch of the ONYX 3200, a new semiconductor metrology system to measure film thickness, composition and bump* structures for wafer-level processes. The system is engineered to help manufacturers stabilize quality and increase yield in the metal-wiring formation (back-end-of-line (BEOL)) and packaging processes of semiconductor chips. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216597402/en/ ONYX 3200 Due to accelerating demands for AI, high-performance computing, data centers, mobile devices, and other devices, chip wiring and interconnect structures have grown increasingly delicate and complex. As a
Taylor Wessing Diversifies Its International Strategy17.12.2025 15:05:00 CET | Press release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 15:00:00 CET | Press release
ISACA appointed to certify professionals assessing organisations against the US Department of War’s (DoW) Cybersecurity Maturity Model Certification (CMMC) programme.New requirements mean that all global businesses supplying to US DoW will need to be compliant with this framework, impacting over 200,000 organisationsAppointment supports global demand for consistent, verifiable cyber maturity amid escalating cyber threats and growing assessor shortages.The Cyber AB remains the official accreditation body for the CMMC programme, authorizing the CAICO and other CMMC ecosystem parties As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom